Brief: EMA's CHMP Says Positive Opinion Was Adopted For Blenrep - Website
23/05/2025 12:32
May 23 (Reuters) - EMA: EMA'S CHMP SAYS POSITIVE OPINION WAS ADOPTED FOR BLENREP - WEBSITE EMA'S CHMP: RECOMMENDS GRANTING CONDITIONAL MARKETING AUTHORISATION FOR AUCATZYL EMA'S CHMP: ITOVEBI (INAVOLISIB) RECEIVED A POSITIVE OPINION EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR IMFINZI, REZOLSTA, SAXENDA & TEVIMBRA Source text: [ID:] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants